# ZSDT for the Treatment of R/R Mantle Cell Lymphoma After BTK Inhibitor Failure: a Multi-center Prospective Clinical Trial

> **NCT07264894** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Zhengzhou University** · enrollment: 30 (estimated)

## Conditions studied

- Mantle Cell Lymphoma (MCL)

## Interventions

- **DRUG:** ZSDT regimen

## Key facts

- **NCT ID:** NCT07264894
- **Lead sponsor:** Zhengzhou University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12-31
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07264894

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07264894, "ZSDT for the Treatment of R/R Mantle Cell Lymphoma After BTK Inhibitor Failure: a Multi-center Prospective Clinical Trial". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT07264894. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*